Athersys, Inc. (ATHX) Social Stream



Athersys, Inc. (ATHX): $1.76

-0.02 (-1.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ATHX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 491

in industry

Featured Post From StockTwits About ATHX

$ATHX THIS is how I like to see offerings written! This is another stock I have that is on the OTC (Nexcf). It’s currently down pretty big from normal trading around $3/shares. Offering is for $5/shares with half a warrant for each share purchased to buy more at $6/shares between now and 2023 of the stock trades at $10/share for 15-consecutive days or more. THAT is management that knows they’re going somewhere! And I got these shares for free at $0.40/each like 2 years ago from the spinoff of MCIG.
ChikinWNG, published April 8, 2021

Other Notable StockTweets About ATHX


$ATHX I wish I could convince more family members to invest. I know, I know if it fails that can hurt relationships. But I think it is a conservative estimate to think that one bridge is a success and that the current price will more than double. How often do we as investors have knowledge like this this early. There is always risk of course. The treasure trial could fail and most of us longs will probably hold till treasure results. At that point some of our gains would be lost. But even then it seems unlikely that the gains would fall below current price levels. I am not buying anymore as I realized last fall that I had to put a stop somewhere but it is really difficult to keep from buying more.

Anyway, Happy Easter to all. While I am only 90 percent sure of positive one bridge results I am sure that He has Risen Indeed. This is the investment I hope I will be making at all times.

worktofish, published April 4, 2021

$ATHX $17.3 mil cash used for operating activities in Q4 2020. As of March 19, they have $61.5 mil cash on hand. At the Q4 burn rate, they would have enough cash to last into Q1 2022. There is no immediate need to conduct a secondary offering. If the Healios data in stroke and/or ARDS is good there will be a significant increase in the share price. That would be the opportune time to raise capital, if they decide to do so. They will also be entitled to large development milestone payments from Healios for both indications. They can also use the Aspire ATM (if needed) to add to their cash total. Healios will be reporting that enrollment is complete in both trials very soon as they had over 90% completion a couple of months ago.

Don’t sell your shares for pennies or a loss. This stock will worth MUCH more in the coming months.

Last thing, ignore the bad actors like @Bers2 @nate_the_great_zanno as they will try to scare you into selling.

Good luck!

CavScout1969, published March 28, 2021

$ATHX TSOI and CELZ
👉 check these out, maybe you can add to your portfolio but if not interested please ignore!
👉 TSOI 52 week high was 0.173 and CELZ was 0.130. I think we will reach those highs and surpass them in the near future with this breakthrough biotechnology! The accomplishments of both of these companies will be life changing for millions of people around the world and maybe even for someone in your immediate family!Good luck guys! https://www.otcmarkets.com/stock/CELZ/news

https://therapeuticsolutionsint.com/patents/

https://board.therapeuticsolutionsint.com/viewforum.php?f=2

tempotrader, published March 21, 2021

$ATHX
If their conclusion doesn’t say, what else does an investor need???

Conclusions: MAPC provide a uniquely robust therapeutic effect on clinically relevant neurological and morphological outcomes in two different ICH models. MAPC also reduced bleeding in the COL model, suggesting the potential for MAPC as a safe acute therapeutic treatment after ICH. In addition to having beneficial effects on recovery processes, MAPC could be further evaluated as a candidate to limit the hematoma enlargement during the initial postictal period. We are currently investigating the mechanism of MAPC-induced post-ICH recovery as well as hemostasis using tissue microarray analysis.

robstr, published March 12, 2021

Loading social stream, please wait...



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6532 seconds.